Neogen Stock Forecast, Price & News

-1.37 (-2.98 %)
(As of 06/18/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume14,100 shs
Average Volume393,996 shs
Market Capitalization$4.78 billion
P/E Ratio76.98
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NEOG News and Ratings via Email

Sign-up to receive the latest news and ratings for Neogen and its competitors with MarketBeat's FREE daily newsletter.

Neogen logo

About Neogen

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.36 out of 5 stars

Medical Sector

792nd out of 2,100 stocks

Diagnostic Substances Industry

13th out of 35 stocks

Analyst Opinion: 1.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Neogen (NASDAQ:NEOG) Frequently Asked Questions

Is Neogen a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neogen in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Neogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEOG, but not buy additional shares or sell existing shares.
View analyst ratings for Neogen
or view top-rated stocks.

What stocks does MarketBeat like better than Neogen?

Wall Street analysts have given Neogen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neogen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Neogen's next earnings date?

Neogen is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for Neogen

How were Neogen's earnings last quarter?

Neogen Co. (NASDAQ:NEOG) released its quarterly earnings data on Monday, March, 22nd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by $0.00. The business earned $116.70 million during the quarter, compared to the consensus estimate of $106.72 million. Neogen had a trailing twelve-month return on equity of 8.03% and a net margin of 13.66%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the company earned $0.06 EPS.
View Neogen's earnings history

How has Neogen's stock been impacted by Coronavirus?

Neogen's stock was trading at $15.1825 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEOG stock has increased by 194.1% and is now trading at $44.65.
View which stocks have been most impacted by COVID-19

When did Neogen's stock split? How did Neogen's stock split work?

Shares of Neogen split on Friday, June 4th 2021. The 2-1 split was announced on Wednesday, May 12th 2021. The newly created shares were issued to shareholders after the market closes on Thursday, June 3rd 2021. An investor that had 100 shares of Neogen stock prior to the split would have 200 shares after the split.

What price target have analysts set for NEOG?

3 Wall Street analysts have issued 1-year target prices for Neogen's shares. Their forecasts range from $18.75 to $22.00. On average, they anticipate Neogen's stock price to reach $20.38 in the next year. This suggests that the stock has a possible downside of 54.4%.
View analysts' price targets for Neogen
or view top-rated stocks among Wall Street analysts.

Who are Neogen's key executives?

Neogen's management team includes the following people:
  • Mr. John Edward Adent, Pres, CEO & Director (Age 53, Pay $723.53k)
  • Mr. Steven J. Quinlan, VP, CFO & Sec. (Age 59, Pay $280.65k)
  • Sarah Demey, Admin. Mang.
  • Ms. Amy Rocklin Ph.D., VP & Gen. Counsel
  • Mr. Rod Poland, Director of Corp. Communications
  • Ms. Julie A. Mann, VP & Chief HR Officer (Age 56)
  • Mr. Doug Jones, Chief Commercial Officer

What is John Adent's approval rating as Neogen's CEO?

31 employees have rated Neogen CEO John Adent on John Adent has an approval rating of 56% among Neogen's employees. This puts John Adent in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neogen's key competitors?

What other stocks do shareholders of Neogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neogen investors own include NVIDIA (NVDA), NIKE (NKE), Pfizer (PFE), AT&T (T), AbbVie (ABBV), The Boeing (BA), JPMorgan Chase & Co. (JPM), W. P. Carey (WPC), Advanced Micro Devices (AMD) and Costco Wholesale (COST).

What is Neogen's stock symbol?

Neogen trades on the NASDAQ under the ticker symbol "NEOG."

Who are Neogen's major shareholders?

Neogen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (12.12%), BlackRock Inc. (11.71%), Wasatch Advisors Inc. (6.14%), Fred Alger Management LLC (4.00%), Conestoga Capital Advisors LLC (3.51%) and Riverbridge Partners LLC (2.51%). Company insiders that own Neogen stock include Bruce Papesh, Jack C Parnell, James L Herbert, James P Tobin, Jason Warren Lilly, John Edward Adent, Steven J Quinlan, Terri A Morrical, Thomas H Reed and William T Boehm.
View institutional ownership trends for Neogen

Which major investors are selling Neogen stock?

NEOG stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mitsubishi UFJ Trust & Banking Corp, Ameriprise Financial Inc., Man Group plc, Glenmede Trust Co. NA, Riverbridge Partners LLC, Credit Suisse AG, and Prudential Financial Inc.. Company insiders that have sold Neogen company stock in the last year include Bruce Papesh, James L Herbert, Jason Warren Lilly, John Edward Adent, Steven J Quinlan, Terri A Morrical, and William T Boehm.
View insider buying and selling activity for Neogen
or view top insider-selling stocks.

Which major investors are buying Neogen stock?

NEOG stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Allianz Asset Management GmbH, BlackRock Inc., Fred Alger Management LLC, JPMorgan Chase & Co., Geode Capital Management LLC, Stephens Investment Management Group LLC, and Sei Investments Co.. Company insiders that have bought Neogen stock in the last two years include James P Tobin, and John Edward Adent.
View insider buying and selling activity for Neogen
or or view top insider-buying stocks.

How do I buy shares of Neogen?

Shares of NEOG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neogen's stock price today?

One share of NEOG stock can currently be purchased for approximately $44.65.

How much money does Neogen make?

Neogen has a market capitalization of $4.78 billion and generates $418.17 million in revenue each year. The company earns $59.47 million in net income (profit) each year or $0.56 on an earnings per share basis.

How many employees does Neogen have?

Neogen employs 1,764 workers across the globe.

When was Neogen founded?

Neogen was founded in 1982.

What is Neogen's official website?

The official website for Neogen is

Where are Neogen's headquarters?

Neogen is headquartered at 620 LESHER PLACE, LANSING MI, 48912.

How can I contact Neogen?

Neogen's mailing address is 620 LESHER PLACE, LANSING MI, 48912. The company can be reached via phone at 517-372-9200 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.